Summary

Other Scenarios:

Buyer: Gilead Sciences, Inc. (GILD) Last Price: 54.72 Market Cap.: 50.48B
Target: Amgen, Inc. (AMGN) Last Price: 45.17 Market Cap.: 49.18B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 879
Biopharmaceuticals 363

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 22)
  • Darusentan
  • Letairis (Ambrisentan)
  • Flolan (Epoprostenol Sodium)
  • Viread (Tenofovir Disoproxil Fumarate)
Target (Total: 36)
  • CK-1827452 (Cardiac Myosin Activator)
  • Enbrel/Enbrel Once-Weekly (Etanercept)
  • AMG 714 (Interleukin-15)
  • AMG 714
Buyer

n/a
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 9)
  • DATATRAK International, Inc. (DATA)
  • Novartis AG (ADR) (NVS)
  • Abbott Laboratories (ABT)
  • Pharsight Corporation (PHST)
Target (Total: 27)
  • NPS Pharmaceuticals, Inc. (NPSP)
  • Bioject Medical Technologies Inc. (BJCT)
  • Starlims Technologies Limited (LIMS)
  • Genentech, Inc. (DNA)
Buyer (Total: 8)
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
  • Roche Holding Ltd. (ADR) (RHHBY)
Target (Total: 15)
  • AmerisourceBergen Corp. (ABC)
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • Johnson & Johnson (JNJ)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 2,979 17,500
Revenue Per Employee 1,694,003.0 828,097.3
Total Revenue 1,258.2 3,613.0
Total Expenses 590.1 2,198.0
Other Revenue 0.0 0.0
Cost of Revenue 239.8 546.0
SG&A Expense 195.0 874.0
Research & Development 155.3 694.0
Other Operating Expense 0.0 0.0
Operating Income 668.0 1,415.0
Unusual Income 0.0 10.0
LT Debt to Capital 28.08 32.47
Fwd P/E 27.19 11.13
Fwd P/Rev 9.93 3.39
Book Value 3,329.5 19,087.0
Curr Portion of LTD/Cap Lease 0.2 2,000.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Target

Focused (): Healthcare > Biopharmaceuticals > Hematology

Business Description

Buyer

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, the United Kingdom and the United States. Its commercial teams promote Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis and Flolan through direct field contact with physicians, hospitals, clinics and other healthcare providers. Its corporate partner, Astellas Pharma, Inc. (Astellas), promotes, sells and distributes AmBisome in the United States.In September 2007, it acquired Nycomed Limited, a wholly owned Irish subsidiary of Germany-based pharmaceutical company, Nycomed GmbH.

Target

Amgen Inc. is a biotechnology company that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company operates in human therapeutics. It markets human therapeutic products in the areas of supportive cancer care, nephrology, inflammation and oncology. Its principal products include Aranesp (darbepoetin alfa), EPOGEN (Epoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and Enbrel (etanercept). Aranesp and EPOGEN stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis-stimulating agents (ESAs). Other marketed products principally consists of Sensipar (cinacalcet HCl) and Vectibix (panitumumab). On July 16, 2007, the Company acquired Alantos Pharmaceuticals Holding, Inc.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 81.23 82.98
Operating Margin % 50.95 27.18
Quick Ratio 2.02 1.83
Current Ratio 3.14 2.44
Coverage Ratio 0.05 0
Total Assets 5,879.0 36,128.0
Return on Equity % 51.18 16.72
Return on Assets % 28.98 8.83
Cash+ ST Inv. Per Share 0.95 7.92
Total Debt 1,300.2 11,177.0
Total Debt to Equity % 39.05 58.56
Total Debt to Tangible Equity % 39.05 250.1
Debt to Asset % 22.12 30.94

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • CK-1827452 (Cardiac Myosin Activator)
  
Vascular Disorders  
Hypertension  
Endothelin Receptor Antagonists
Therapeutics that treat hypertension by blocking the action of endothelin, which prevents/reduces constriction of the blood vessels.

Buyer Products:

  • Darusentan
  
Primary Pulmonary Hypertension  
Endothelin Receptor Antagonists
Therapeutics that treat hypertension by blocking the action of endothelin, which prevents/reduces constriction of the blood vessels.

Buyer Products:

  • Letairis (Ambrisentan)
  
Prostacyclins
Therapeutics that relieve pulmonary hypertension by causing vasodilation of the pulmonary blood vessels.

Buyer Products:

  • Flolan (Epoprostenol Sodium)
  
Dermatology  
Lesion/Scaling Disorders  
Psoriasis  
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.

Target Products:

  • Enbrel/Enbrel Once-Weekly (Etanercept)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Target Products:

  • AMG 714 (Interleukin-15)
  • AMG 714
  
Digestive System
Gastrointestinal Tract Disorders  
Stomatognathic Disorders  
Mucositis  
Keratinocyte Growth Factor (KGF)
Therapeutics that treat mucositis by promoting the growth of keratinocytes, which are cells found in the epidermis or outer layer of skin.

Target Products:

  • Kepivance (Palifermin)
  
Liver Disorders  
Hepatitis  
Hepatitis B  
Chronic  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat hepatitis by inhibiting the action of reverse transcriptase, an enzyme necessary for DNA synthesis using an RNA template.

Buyer Products:

  • Viread (Tenofovir Disoproxil Fumarate)
  • Hepsera (Adefovir Dipivoxil)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • LB84451 (Pan-Caspase Inhibitor)
  • GS 9190 (HCV Polymerase Inhibitor)
  • Emtriva (Emtricitabine)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • NS4A Antagonists
  • HCV Protease And Polymerase Inhibitors
  
Endocrinology/Metabolism  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Target Products:

  • AMG 477
  • AMG 222/ALS 2-0426 (DPP-IV Inhibitor)
  • Sensipar (Cinacalcet Hydrochloride)
  • AMG 837
  • AMG 221
  
Hematology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Nplate (Romiplostim)
  • AMG 223/Formerly ILY101
  
Red Blood Cell (RBC) Disorders  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.

Target Products:

  • Epogen (Epoetin Alfa)
  • Aranesp (Darbepoetin Alfa)/Aranesp Prefilled SureClick
  
White Blood Cell (WBC) Disorders  
Neutropenia  
Colony Stimulating Factors (CSF)  
Granulocyte (rhG-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of white blood cells.

Target Products:

  • Neulasta (Pegylated Filgrastim)
  • Neupogen (Filgrastim)
  
Immunology
Autoimmune Disorders  
Arthritis  
Psoriatic Arthritis  
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints coupled with red, scaly skin patches by blocking the action of tumor necrosis factor.

Target Products:

  • Enbrel/Enbrel Once-Weekly (Etanercept)
  
Rheumatoid Arthritis (RA)  
Immunotherapy  
Interleukin-1 Receptor Antagonists (IL-1 Antagonists)
Therapeutics that treat chronic inflammation of the joints caused by an autoimmune mechanism by blocking the action of Interleukin-1.

Target Products:

  • Kineret (Anakinra)
  
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.

Target Products:

  • Enbrel/Enbrel Once-Weekly (Etanercept)
  
Idiopathic Thrombocytopenia Purpura (ITP)  
Platelet Growth Factors
Therapeutics that treat a decrease in platelets by promoting platelet production.

Target Products:

  • Nplate (Romiplostim)
  
Psoriasis  
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.

Target Products:

  • Enbrel/Enbrel Once-Weekly (Etanercept)
  
Immune Deficiency Disorders  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Viread (Tenofovir Disoproxil Fumarate)
  • Emtriva (Emtricitabine)
  • Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine)
  
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9137 (HIV Integrase Inhibitor)

Target Products:

  • Denosumab
  • AMG 714 (Interleukin-15)
  • AMG 811
  • AMG 827
  • AMG 714
  • AMG 761/KW-0761 (Anti-CCR4 Humanized Monoclonal Antibody)
  • AMG 557
  • AMG 108
Infectious Diseases  
Mycological (Fungal)  
Antifungal Agents  
Broad Spectrum  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections by increasing permeability of the cell wall causing leakage of cellular contents.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Narrow Spectrum  
Nervous System  
Cryptococcal Meningitis  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the lining of the brain and spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9137 (HIV Integrase Inhibitor)
  • LB84451 (Pan-Caspase Inhibitor)
  • GS 9190 (HCV Polymerase Inhibitor)
  
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Visceral Leishmaniasis  
Polyene Macrolide Antibiotics
Therapeutics that treat infections characterized by Leishmania in macrophages by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Inhaled Therapeutics
  • Tamiflu (Oseltamivir)
  
Viral  
DNA Viruses  
Hepadnavirus  
Hepatitis B  
Chronic  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months by blocking enzyme essential for viral DNA synthesis.

Buyer Products:

  • Emtriva (Emtricitabine)
  • Viread (Tenofovir Disoproxil Fumarate)
  • Hepsera (Adefovir Dipivoxil)
  
RNA Viruses  
Orthomyxovirus  
Influenza A  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Influenza B  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Viread (Tenofovir Disoproxil Fumarate)
  • Emtriva (Emtricitabine)
  • Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine)
  
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Sclerostin Ab/AMG 785
  • Denosumab
  • AMG 108
  • AMG 745
  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Receptor Activator Of Nuclear Factor-kB Ligand (RANKL) Inhibitors
Therapeutics that treat osteoporosis by inhibiting a mediator of osteoclast formation resulting in suppression of bone resorption.

Target Products:

  • Denosumab
  
Joint Disorders  
Ankylosing Spondylitis  
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ankylosing spondylitis by blocking the effect of TNF-alpha, a pro-inflammatory molecule.

Target Products:

  • Enbrel/Enbrel Once-Weekly (Etanercept)
  
Psoriatic Arthritis  
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.

Target Products:

  • Enbrel/Enbrel Once-Weekly (Etanercept)
  
Rheumatoid Arthritis (RA)  
Immunotherapy  
Interleukin-1 Receptor Antagonists (IL-1 Antagonists)
Therapeutics that treat chronic inflammation of the joints caused by an autoimmune mechanism by blocking the action of Interleukin-1.

Target Products:

  • Kineret (Anakinra)
  
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.

Target Products:

  • Enbrel/Enbrel Once-Weekly (Etanercept)
  
Oncology
Breast Cancer  
Localized  
Recombinant Human Erythropoietins
Therapeutics that help to treat breast cancers by increasing the delivery of oxygen to body tissues through stimulating red blood cell production.

Target Products:

  • Aranesp (Darbepoetin Alfa)/Aranesp Prefilled SureClick
  
Metastatic  
Receptor Activator Of Nuclear Factor-kB Ligand (RANKL) Inhibitors
Therapeutics that treat cancer bone metastases by inhibiting a mediator of osteoclast formation resulting in suppression of bone resorption.

Target Products:

  • Denosumab
  
Dermatology  
Kaposi`s Sarcoma  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of spindle cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Buyer Products:

  • DaunoXome (Liposomal Daunorubicin Injection)
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Metastatic  
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Target Products:

  • Vectibix (Panitumumab)
  
Endocrinology  
Parathyroid Gland  
Palliative Agents  
Calcimimetic Agents
Therapeutics that treat hypercalcemia (elevated calcium levels in the blood) by decreasing parathyroid hormone levels.

Target Products:

  • Sensipar (Cinacalcet Hydrochloride)
  
Head/Neck Cancer  
Metastatic  
Monoclonal Antibodies
Therapeutics that treat head/neck cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Target Products:

  • Vectibix (Panitumumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9219 (Nucleotide Analog)

Target Products:

  • AMG 479
  • rhApo2L/TRAIL (PRO1762)
  • Vectibix (Panitumumab)
  • AMG 102
  • AMG 386
  • Denosumab
  • AMG 655
  • Motesanib Diphosphate/Formerly AMG 706
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
VEGFR/PDGFR/SCFR Inhibitors
Therapeutics that treat lung cancer by binding to the vascular endothelial growth factor receptor (VEGFR), the platelet-derived growth factor receptor (PDGFR), and the stem-cell factor receptor (SCFR), which then inhibits the formation of blood vessels around tumor cells.

Target Products:

  • Motesanib Diphosphate/Formerly AMG 706
  
Urology  
Prostate Cancer  
Localized  
Receptor Activator Of Nuclear Factor-kB Ligand (RANKL) Inhibitors
Therapeutics that treat or prevent cancer bone metastases by inhibiting a mediator of osteoclast formation resulting in suppression of bone resorption.

Target Products:

  • Denosumab
  
Metastatic  
Receptor Activator Of Nuclear Factor-kB Ligand (RANKL) Inhibitors
Therapeutics that treat cancer bone metastases by inhibiting a mediator of osteoclast formation resulting in suppression of bone resorption.

Target Products:

  • Denosumab
  
Ophthalmology  
Degenerative Disorders  
Retinitis  
AIDS-Related Cytomegalovirus (CMV) Retinitis  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Vistide (Cidofovir)
  
Pain Management  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Target Products:

  • AMG 403
  • AMG 379
  
Respiratory System
Lower Respiratory Tract Disorders (Lung Disorders)  
Cystic Fibrosis (CF)  
Complications  
Bacterial Infections  
Antibacterial Agents (Antibiotics)  
Monobactams
Therapeutics that treat bacterial infections of the lung resulting as a complication of cystic fibrosis by inhibiting bacterial cell wall synthesis during active multiplication.

Buyer Products:

  • Inhaled Aztreonam Lysine
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9310/11 (Tobramycin And Fosfomycin)

Target Products:

  • AMG 317(IL-4/IL-13 Antibody)
  • AMG 853
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • P-680 (Epithelial Sodium Channel (ENaC) Inhibitor)
  
Surgery  
General  
Complications  
Hemorrhage  
Recombinant Human Erythropoietins
Therapeutics that are used for blood transfusions.

Target Products:

  • Epogen (Epoetin Alfa)
  
Transplantation  
Bone Marrow  
Complications  
Neutropenia  
Colony Stimulating Factors (CSF)  
Granulocyte (rhG-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cells called granulocytes.

Target Products:

  • Neupogen (Filgrastim)
  
Peripheral Blood Progenitor Cell Transplant (PBPCT)  
Preparation  
Colony Stimulating Factors (CSF)  
Granulocyte (rhG-CSF)
Therapeutics that stimulate the formation of granulocytes in preparation for peripheral blood progenitor cell transplantation.

Target Products:

  • Neupogen (Filgrastim)
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Sensipar (Cinacalcet Hydrochloride)
  • AMG 223/Formerly ILY101
  
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat the condition resulting from the scarcity of red blood cells by inducing the production of red blood cells.

Target Products:

  • Aranesp (Darbepoetin Alfa)/Aranesp Prefilled SureClick
  • Epogen (Epoetin Alfa)
  
Hyperparathyroidism  
Calcimimetic Agents
Therapeutics that treat hyperparathyroidism by decreasing parathyroid hormone levels, which may provide effective reduction of calcium levels.

Target Products:

  • Sensipar (Cinacalcet Hydrochloride)
  
Renal Insufficiency  
Complications  
Hyperparathyroidism  
Calcimimetic Agents
Therapeutics that treat hyperparathyroidism by decreasing parathyroid hormone levels, which may provide effective reduction of calcium levels.

Target Products:

  • Sensipar (Cinacalcet Hydrochloride)
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Johnson & Johnson n/a 180,533.379 15.56 14.52 2.90 2.83 11.15
Roche Holding Ltd. (ADR) n/a 142,150.304 14.93 15.56 3.16 3.31 4.53
Novartis AG (ADR) n/a 117,403.542 9.71 13.83 2.95 2.80 4.28
Pfizer Inc. n/a 117,240.865 15.56 7.53 2.45 2.50 4.52
GlaxoSmithKline plc (ADR) n/a 114,978.038 11.65 11.19 2.56 2.54 19.06
Abbott Laboratories n/a 82,334.843 21.40 16.76 3.08 2.87 38.10
Genentech, Inc. n/a 78,564.688 25.79 23.83 6.58 6.09 7.55
Bristol Myers Squibb Co. n/a 38,740.734 18.14 11.93 1.92 1.86 9.06
Shire Ltd. (ADR) n/a 8,831.991 n/a 15.73 3.38 3.04 n/a
Vertex Pharmaceuticals Incorporated n/a 4,689.385 n/a -11.53 27.28 23.89 15.41
Dynavax Technologies Corporation n/a 58.912 n/a -1.59 3.20 2.41 4.22
Buyer
  Johnson & Johnson n/a 180,533.379 15.56 14.52 2.90 2.83 11.15
Roche Holding Ltd. (ADR) n/a 142,150.304 14.93 15.56 3.16 3.31 4.53
Target
  The Procter & Gamble Company n/a 192,826.540 17.09 18.54 2.37 2.38 n/a
Johnson & Johnson n/a 180,533.379 15.56 14.52 2.90 2.83 11.15
Roche Holding Ltd. (ADR) n/a 142,150.304 14.93 15.56 3.16 3.31 4.53
Novartis AG (ADR) n/a 117,403.542 9.71 13.83 2.95 2.80 4.28
Pfizer Inc. n/a 117,240.865 15.56 7.53 2.45 2.50 4.52
GlaxoSmithKline plc (ADR) n/a 114,978.038 11.65 11.19 2.56 2.54 19.06
Sanofi-Aventis SA (ADR) n/a 88,302.731 11.35 7.73 1.96 2.03 n/a
Abbott Laboratories n/a 82,334.843 21.40 16.76 3.08 2.87 38.10
Genentech, Inc. n/a 78,564.688 25.79 23.83 6.58 6.09 7.55
Eli Lilly & Co. n/a 53,358.236 15.21 12.16 2.78 2.67 4.26
Bristol Myers Squibb Co. n/a 38,740.734 18.14 11.93 1.92 1.86 9.06
Celgene Corporation n/a 25,968.914 n/a 45.74 16.49 12.06 13.19

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pharsight Corporation n/a 43.372 n/a 16.70 1.53 1.30 4.41
Buyer
  DATATRAK International, Inc. 14.00% 6.584 n/a n/a 0.72 n/a 2.03
Novartis AG (ADR) n/a 117,403.542 9.71 13.83 2.95 2.80 4.28
Target
  NPS Pharmaceuticals, Inc. 65.80% 202.971 53.88 -5.48 2.00 2.24 n/a
Bioject Medical Technologies Inc. 15.00% 6.113 n/a n/a 0.76 n/a 2.42
Starlims Technologies Limited 9.00% 57.157 11.99 11.17 2.26 2.06 1.32
Genentech, Inc. n/a 78,564.688 25.79 23.83 6.58 6.09 7.55
Agilent Technologies Inc. n/a 13,529.265 20.59 19.74 2.39 2.32 5.91
WPP Group plc (ADR) n/a 12,030.518 13.27 11.23 1.00 0.47 n/a
Medarex inc. n/a 921.440 n/a -5.40 16.25 19.55 2.33
Human Genome Sciences n/a 765.211 n/a -4.36 17.06 4.65 n/a
Hill International Inc. n/a 707.401 38.20 27.32 2.29 2.01 7.91
Pegasystems Inc. n/a 475.259 55.79 n/a 2.75 n/a 2.89
Dendreon Corporation n/a 462.254 n/a -5.27 668.46 300.54 20.43
CRA International, Inc. n/a 439.327 20.42 17.28 1.09 1.10 5.65
Sangamo Biosciences, Inc. n/a 370.196 n/a -12.43 35.45 24.11 5.75
Dyax Corp. n/a 227.744 n/a -3.20 8.72 10.19 26.67
Cytokinetics, Inc. n/a 197.205 n/a -2.79 14.62 15.81 2.28
Callidus Software Inc. n/a 178.027 n/a -29.05 1.70 1.58 4.03
Infinity Pharmaceuticals Inc. n/a 151.062 n/a -4.99 5.07 5.57 2.84
Harvard Bioscience, Inc. n/a 146.896 n/a 13.88 1.70 n/a 4.00
Caliper Life Sciences Inc. n/a 144.300 n/a -14.43 1.02 1.00 12.33
ImmunoGen, Inc. n/a 129.155 n/a -4.26 2.92 2.78 3.12
Saba Software, Inc. n/a 100.766 n/a 45.75 0.96 0.98 n/a
Pharsight Corporation n/a 43.372 n/a 16.70 1.53 1.30 4.41

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Cardinal Health, Inc. 20.00% 18,435.537 9.78 13.84 0.20 0.20 10.77
McKesson Corporation 15.00% 15,829.870 15.99 14.63 0.16 0.14 6.14
AmerisourceBergen Corp. 11.00% 6,405.129 13.89 14.11 0.09 0.09 n/a
Buyer
  Cardinal Health, Inc. 20.00% 18,435.537 9.78 13.84 0.20 0.20 10.77
McKesson Corporation 15.00% 15,829.870 15.99 14.63 0.16 0.14 6.14
AmerisourceBergen Corp. 11.00% 6,405.129 13.89 14.11 0.09 0.09 n/a
Roche Holding Ltd. (ADR) 10.00% 142,150.304 14.93 15.56 3.16 3.31 4.53
OSI Pharmaceuticals, Inc. n/a 2,289.587 25.75 18.92 6.46 6.08 38.84
XenoPort, Inc. n/a 1,060.600 43.76 -29.09 9.45 19.61 8.71
Rexahn Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  AmerisourceBergen Corp. 31.00% 6,405.129 13.89 14.11 0.09 0.09 n/a
Cardinal Health, Inc. 14.00% 18,435.537 9.78 13.84 0.20 0.20 10.77
McKesson Corporation 12.00% 15,829.870 15.99 14.63 0.16 0.14 6.14
Johnson & Johnson n/a 180,533.379 15.56 14.52 2.90 2.83 11.15
Fresenius Medical Care AG & Co. (ADR) n/a 15,813.405 21.29 19.30 1.60 1.51 n/a
DaVita Inc. n/a 5,418.225 13.82 15.06 1.02 0.97 n/a
Amylin Pharmaceuticals, Inc. n/a 3,562.535 n/a -13.28 4.42 4.00 6.44
InterMune, Inc. n/a 570.487 n/a -5.81 10.25 13.26 n/a
Progenics Pharmaceuticals, Inc. n/a 520.280 n/a -16.08 7.15 5.54 3.77
Cell Genesys, Inc. n/a 244.930 n/a -2.54 18.11 6.49 14.22
Dialysis Corporation of America n/a 68.495 21.74 21.45 0.88 0.79 3.11
Nuvelo, Inc. n/a 29.963 n/a -0.80 0.65 4.03 0.65
Memory Pharmaceuticals Corp. n/a 29.818 n/a -0.74 3.11 7.27 n/a
Targeted Genetics Corporation n/a 13.275 n/a -0.87 1.19 n/a 2.61
Takeda Pharmaceutical Company Limited n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Roche Holding Ltd. (ADR) n/a 142,150.304 14.93 15.56 3.16 3.31 4.53
Cardinal Health, Inc. n/a 18,435.537 9.78 13.84 0.20 0.20 10.77
McKesson Corporation n/a 15,829.870 15.99 14.63 0.16 0.14 6.14
AmerisourceBergen Corp. n/a 6,405.129 13.89 14.11 0.09 0.09 n/a
Medarex inc. n/a 921.440 n/a -5.40 16.25 19.55 2.33
Buyer
  Roche Holding Ltd. (ADR) n/a 142,150.304 14.93 15.56 3.16 3.31 4.53
Novartis AG (ADR) n/a 117,403.542 9.71 13.83 2.95 2.80 4.28
Target
  Johnson & Johnson n/a 180,533.379 15.56 14.52 2.90 2.83 11.15
Roche Holding Ltd. (ADR) n/a 142,150.304 14.93 15.56 3.16 3.31 4.53
Genentech, Inc. n/a 78,564.688 25.79 23.83 6.58 6.09 7.55
Wyeth n/a 63,800.222 13.99 13.86 2.81 2.81 4.32
Alcon, Inc. n/a 48,317.276 28.94 26.04 8.31 7.77 15.06
Cardinal Health, Inc. n/a 18,435.537 9.78 13.84 0.20 0.20 10.77
McKesson Corporation n/a 15,829.870 15.99 14.63 0.16 0.14 6.14
Fresenius Medical Care AG & Co. (ADR) n/a 15,813.405 21.29 19.30 1.60 1.51 n/a
Kirin Holdings Company, Limited. (ADR) n/a 14,368.676 31.02 26.62 0.94 0.83 2.47
AmerisourceBergen Corp. n/a 6,405.129 13.89 14.11 0.09 0.09 n/a
DaVita Inc. n/a 5,418.225 13.82 15.06 1.02 0.97 n/a
Amylin Pharmaceuticals, Inc. n/a 3,562.535 n/a -13.28 4.42 4.00 6.44
Inverness Medical Innovations, Inc. n/a 2,475.000 n/a 18.33 2.35 1.60 n/a
Regeneron Pharmaceuticals, Inc. n/a 1,161.279 n/a -11.30 7.01 6.67 2.52
Medarex inc. n/a 921.440 n/a -5.40 16.25 19.55 2.33
Human Genome Sciences n/a 765.211 n/a -4.36 17.06 4.65 n/a
InterMune, Inc. n/a 570.487 n/a -5.81 10.25 13.26 n/a
ZymoGenetics, Inc. n/a 524.860 n/a -3.89 11.21 7.31 6.67

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 4,459.8 14,697.0 19,156.8
Other Revenue 0.0 0.0 0.0
Total Revenue 4,459.8 14,697.0 19,156.8
Cost of Revenue 837.0 2,502.0 3,339.0
SG&A Expense 734.1 3,465.0 4,199.1
Depreciation & Amortization 0.0 298.0 298.0
Research & Development 616.2 3,109.0 3,725.2
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 728.0 728.0
Unusual Expense (Income) 0.0 600.0 600.0
Total Expenses 2,187.4 10,702.0 12,889.4
Operating Income 2,272.4 3,995.0 6,267.4
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 106.6 9.0 115.6
Other, Net 0.0 0.0 0.0
Income Before Taxes 2,379.0 4,004.0 6,383.0
Income Taxes 675.0 813.0 1,488.0
Income After Taxes 1,704.0 3,191.0 4,895.0
Net Income - Excl. Xord. Items 1,704.0 3,191.0 4,895.0
Net Income - Incl. Xord. Items 1,704.0 3,191.0 4,895.0
Income Avail. to Common 1,704.0 3,191.0 4,895.0
Share Items
Basic Avg. Shares Outstanding 928.1 1,089.0 2,017.1
Basic EPS - Excl. Xord. Items 1.84 2.93 2.43
Basic EPS - Incl. Xord. Items 1.84 2.93 2.43
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 966.6 1,092.0 2,058.6
F.D. EPS - Excl. Xord. Items 1.76 2.92 2.38
F.D. EPS - Incl. Xord. Items 1.76 2.92 2.38
Balance Sheet
Assets
Cash and Equivalents 722.9 4,324.0 5,046.9
ST Investments 191.3 4,323.0 4,514.3
Accounts Receivable 979.8 2,224.0 3,203.8
Inventory 661.1 2,091.0 2,752.1
Prepayments and Advances 147.4 0.0 147.4
Other Current Assets 245.8 1,565.0 1,810.8
Current Assets 2,948.3 14,527.0 17,475.3
Accum D&A 0.0 0.0 0.0
PPE, Net 455.8 5,949.0 6,404.8
Goodwill & Intangibles 0.0 14,618.0 14,618.0
Long Term Investments 1,674.8 0.0 1,674.8
Other Assets 0.0 0.0 0.0
Other LT Assets 800.2 1,034.0 1,834.2
Total Assets 5,879.0 36,128.0 42,007.0
Liabilities
Accounts Payable 396.2 522.0 918.2
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 491.5 3,432.0 3,923.5
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 0.2 2,000.0 2,000.2
Other (Current) Liabilities 51.0 0.0 51.0
Current Liab. 939.0 5,954.0 6,893.0
LT Debt 1,300.0 9,177.0 10,477.0
Total LT Debt 1,300.0 9,177.0 10,477.0
Minority Interest (BS) 110.0 0.0 110.0
Deferred Taxes 0.0 381.0 381.0
Other LT Liab. 200.5 1,529.0 1,729.5
Total Liabilities 2,549.5 17,041.0 19,590.5
Shareholders Equity
Common Stock 0.9 0.0 0.9
Additional Paid in Capital 3,371.1 25,088.0 28,459.1
Retained Earnings -34.6 -6,031.0 -6,065.6
Other Equity -7.9 30.0 22.1
Total Equity 3,329.5 19,087.0 22,416.5
Total Liab. & Equity 5,879.0 36,128.0 42,007.0
Shares Outstanding 921.4 1,088.0 2,009.4
Cash Flow
Operating Cash Flow
CF Net Income 1,704.0 3,191.0 4,895.0
CF Depreciation 40.2 1,224.0 1,264.2
CF Amortization 16.2 0.0 16.2
CF Deferred Taxes 134.6 136.0 270.6
Other Non-Cash Items 223.6 1,161.0 1,384.6
Change in Working Capital -266.5 378.0 111.5
Total Cash From Operating Activities 1,852.0 6,090.0 7,942.0
Investing Cash Flow (not calculated)
Capital Expenditures -70.4 -1,112.0 -1,182.4
Other Investing Cash Flows -764.9 -1,110.0 -1,874.9
Total Cash From Investing Activities -835.3 -2,222.0 -3,057.3
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock -1,078.2 -4,396.0 -5,474.2
Purchase and Retirement of Debt -0.4 3,844.0 3,843.6
Other Financing Cash Flow 131.8 -59.0 72.8
Total Cash From Financing Activities -946.8 -611.0 -1,557.8
Exchange Rate Effects -76.2 0.0 -76.2
Net Change in Cash -6.3 3,257.0 3,250.7
Cash Taxes Paid 565.2 895.0 1,460.2
Cash Interest Paid 7.5 258.0 265.5